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Abstract
Background
Parkinson’s disease is caused by dopaminergic neurodegeneration resulting in motor
impairments as slow movement speed and impaired balance and coordination. Pulsed elec-
tromagnetic fields are suggested to have neuroprotective effects, and could alleviate
symptoms.
Objective
To study 1) effects of 8-week daily transcranial pulsed electromagnetic field treatment on
functional rate of force development and movement speed during two motor tasks with dif-
ferent levels of complexity, 2) if treatment effects depend on motor performance at baseline.
Methods
Ninety-seven persons with Parkinson’s disease were randomized to active transcranial
pulsed electromagnetic field (squared bipolar 3 ms pulses, 50 Hz) or placebo treatment with
homebased treatment 30 min/day for 8 weeks. Functional rate of force development and
completion time of a sit-to-stand and a dynamic postural balance task were assessed pre
and post intervention. Participants were sub-grouped in high- and low-performers according
to their baseline motor performance level. Repeated measure ANOVAs were used.
Results
Active treatment tended to improve rate of force development during chair rise more than
placebo (P = 0.064). High-performers receiving active treatment improved rate of force
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development during chair rise more than high-performers receiving placebo treatment (P =
0.049, active/placebo: 11.9±1.1 to 12.5±1.9 BW/s 5% / 12.4±1.3 to 12.2±1.3 BW/s, no
change). No other between-treatment-group or between-treatment-subgroup differences
were found. Data on rate of force development of the dynamic balance task and completion
times of both motor tasks improved but did not allow for between-treatment differentiation.
Conclusion
Treatment with transcranial pulsed electromagnetic fields was superior to placebo regarding
functional rate of force development during chair rise among high-performers. Active treat-
ment tended to increase functional rate of force development while placebo did not. Our
results suggest that mildly affected persons with Parkinson’s disease have a larger potential
for neural rehabilitation than more severely affected persons and indicate that early treat-
ment initiation may be beneficial.
Introduction
Parkinson’s disease (PD) is a neurodegenerative disease primarily affecting the dopaminergic
neurons in the basal ganglia resulting in functional motor impairments such as slow move-
ment speed (bradykinesia), rigidity, tremor and impaired balance and coordination of move-
ments. The disease influences the ability to activate the muscles fast and without co-activation
of inappropriate muscles [1, 2]. This is reflected in a lower voluntary rate of force development
(RFD) in both isometric and functional setups compared to age-matched healthy peers [2–5]
in spite of an intact capacity of force generation at the muscular level [4]. RFD is important in
performing daily activities where the time available for force generation is short, e.g. managing
balance challenging tasks, response to sudden mechanical perturbations, and safe locomotion.
According to the UK Parkinson’s Disease Society Brain Bank Diagnostic Criteria, the crite-
ria for being diagnosed with PD is bradykinesia along with at least one of the following: mus-
cular rigidity, rest tremor (4–6 Hz) and/or postural instability. Although the diagnostic criteria
are clear, the progression of the disease and the relative severity of a given symptom are quite
heterogenic between patients [6, 7]. This results in heterogeneity of specific motor function.
Therefore, investigations of subgroups based on motor performance may be valuable.
In vitro (cell-line studies) and in vivo (animal studies) treatment with pulsed electromag-
netic fields (PEMF) has been suggested to have potential neuroprotective effects. For example,
PEMF were shown to regulate neutrophic factors such as BDNF, S100 and NGF [8, 9], enhance
cell proliferation and differentiation [8, 10], enhance neurite outgrow [11], reduce apoptosis
[10], stimulate angiogenesis [12], increase microvascular perfusion and tissue oxygenation
[13], and stimulate neurogenesis in the hippocampal dentate gyrus [14] and in the sub ventric-
ular zone after lesion of substantia nigra [15]. The molecular mechanisms initiated by the
applied PEMF are not yet fully understood. However, PEMF may affect the tissue directly by
the interaction mechanism between the electromagnetic fields and conductive tissue, and indi-
rectly by initiating biological events leading to a physiologic response [16].
In healthy humans, PEMF applied transcranially (T-PEMF) has been suggested to acutely
induce enhanced excitatory neurotransmission and/or decreased inhibitory neurotransmis-
sion, though resting or active motor threshold was not affected [17]. This could increase the
capability to activate muscles fast, since an enhanced excitatory neurotransmission may
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facilitate a larger neural drive to the muscles during explosive force production, and thus
increase RFD.
To our knowledge, the effect of T-PEMF on motor function in PD has not previously been
studied, whereas other non-invasive neuromodulation techniques have been shown to
improve motor function in persons with PD. For example, repetitive transcranial magnetic
stimulation was shown to induce positive effects on motor function that last at least a month
[18, 19]. However, transcranial magnetic stimulation usually involves stimulation of the corti-
cal neurons at intensities close to or above the resting motor threshold, and it has to be per-
formed in a clinical setup. On the contrary, the T-PEMF technique uses low intensity
stimulation [16] and may be applicable as a homebased treatment.
Based on the literature, we hypothesized that treatment with T-PEMF has the potential to
improve RFD and movement speed in persons with PD. Our aims were 1) to study the effect
of an 8-week daily homebased T-PEMF treatment on functional RFD and movement speed
during two lower extremity motor tasks with different levels of movement complexity, and 2)
to study if the treatment effect is dependent on motor performance level at baseline.
Methods
Study design
All persons with idiopathic Parkinson’s disease (PDPs) included in the present study were par-
ticipants in a double-blinded block randomized clinical trial investigating the effect of
T-PEMF on PD (clinicaltrials.gov registration# NCT02125032) [20, 21]. PDPs were recruited
from Odense University Hospital and private neurologists in Denmark from May 2014 to
August 2015. They were randomized to receive 8 weeks of active or placebo treatment. The
active and placebo group were of equal size. A third party person conducted the allocation.
PDPs were allocated to a number on the allocation sequence list in order of inclusion. Sample
size calculation for the trial was based on the primary outcome of the trial, The Unified Parkin-
son’s Disease Rating Scale (UPDRS) [20], which is a partly subjective clinical measure of dis-
ease severity based on observations and patient reports. The mean difference on the UPDRS
between active and placebo treatment was estimated to be 3 points from baseline to endpoint
with a pooled standard deviation of this mean difference of 7. With a significance level of 0.05
and a power of 0.80, the sample size was estimated to be 90 participants, i.e. 45 in each treat-
ment group. For details, see S2 Text. The trial was approved by The Regional Scientific Ethical
Committees for Southern Denmark (S-20130114) and The Danish Health Authority (CIV-14-
01-011780), and was conducted in accordance with the Declaration of Helsinki. All partici-
pants provided written informed consent prior to participation. No statistical detectable effect
of T-PEMF relative to placebo treatment was found for the primary outcome [20]. The present
study reports on secondary outcomes.
Participants
Ninety-seven PDPs were included in the clinical trial (Fig 1). Inclusion criteria were a diagno-
sis of idiopathic PD (Hoehn & Yahr I-IV) according to United Kingdom Brain Bank Criteria;
stable and optimal medical treatment regarding PD six weeks prior to and during the interven-
tion period; Mini Mental State Examination >22; age>18 and cognitive skills enabling certifi-
cation in the use of the T-PEMF device. Exclusion criteria were structural brain damage
affecting the ability to give consent; severe psychopathological disturbances; substance abuse;
active medical implants; pregnancy or nursing; current or previous cancer in the brain, neck
or head region; leukemia; autoimmune disease; epilepsy; and open scalp wounds. In addition,
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Fig 1. Participant flow diagram. Flow of participants with Parkinson’s disease (PD) during enrollment, allocation to active
or placebo treatment with transcranial pulsed electromagnetic fields, follow-up after 8 weeks of treatment, and analysis. Sit-
to-stand (STS). Dynamic postural balance (DPB). Completion time of DPB (CTDPB). Functional rate of force development
during DPB (RFDDPB).
https://doi.org/10.1371/journal.pone.0204478.g001
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participants with a post interventional treatment compliance of less than 80% were excluded
from the analyses.
To describe the severity of the disease and medication level, the Unified Parkinson’s Disease
Rating Scale Total score (UPDRS Total) and Motor score (UPDRS Motor) [22] were assessed
and daily levodopa equivalent dose (LED) were calculated according to Tomlinson et al. [23].
In addition, 43 healthy participants matched on age and sex distribution were included
from Dec 2015 to May 2016 as a reference group. The reference group was tested once and
used as a reference frame for subgrouping.
To explore if the baseline performance level of each evaluation parameter had an influence
on the effect of T-PEMF, we divided the PDP group into two subgroups according to their
baseline performance level of each parameter in each task. Since RFD is influenced by age [24]
and all the performance parameters correlated with age (S1 Table), we conducted a linear
regression analysis on each parameter as a function of age in the reference group to gain
expected values of each parameter at a given age. The standard deviation of the parameter of
the whole reference group was used as tolerance. Thus, if a PDP had a baseline RFD value
below the expected mean according to age minus 1 SD (higher values of RFD represent better
performance) he/she was considered a low-performer (PDPLow) of the particular RFD-param-
eter. Equally, if a PDP had a baseline completion time (CT) above the expected mean accord-
ing to age plus 1 SD (lower values of CT represent better performance) he/she was considered
a PDPLow of the particular CT-parameter. Otherwise, a PDP was considered a high-performer
(PDPHigh) of the particular parameter.
T-PEMF treatment
The PDPs received one daily 30-min session of homebased active T-PEMF or placebo treat-
ment for 8 weeks. The T-PEMF device (Re5 NTS Parkinson Treatment System, Re5, Frederiks-
berg, Denmark) consisted of a pulse generator and a head applicator with 7 circular coils
located as follow: one in the central occipital region, one in the frontal-parietal region (bilat-
eral), and two in the anterior-temporal and posterior-temporal region (bilateral). During
active T-PEMF treatment, the pulse generator supplied the coils with squared bipolar pulses of
±50 V at 50 Hz with a pulse duration of 3 ms. The stimulation intensity depends on distance
from coil and also the closeness to the coil in horizontal position. At the periphery of the coil
and close to the skull maximal stimulation was 2.5 mV/cm and decreased with distance [25].
During placebo treatment, no pulsed electromagnetic fields were generated (sham stimula-
tion). The treatment type (active or placebo) was determined by a chip-card inserted in the
pulse generator. A third party person encoded the chip cards. The interface on the pulse gener-
ator had the same appearance no matter if the chip card was encoded with an active T-PEMF
or a placebo treatment. All use of the T-PEMF device was stored on the chip-card and these
records were used to determine treatment compliance. During generation of electromagnetic
fields, the T-PEMF device produced a very faint humming sound (6.1 dB, ~50 Hz, below the
level of detection according to ISO 266:2003) but no heat or skin sensation [26]. Thus, it was
not possible to see or feel difference between active and placebo treatment, and both PDPs and
investigators were blinded to the treatment allocation until all PDPs had completed their treat-
ment period and endpoint assessments.
The PDPs were certified in use of the equipment at baseline. They received a home visit
during the first week of the treatment period to ensure correct use. Furthermore, they received
two telephone calls each week from an investigator to encourage high compliance and register
potential adverse events.
The reference group did not receive any treatment.
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Assessment of motor function
The participants were evaluated on RFD and CT of two motor function tasks: a six-cycle sit-
to-stand (STS) and a dynamic postural balance (DPB) task assessed in a movement laboratory.
Assessments were performed at baseline before the initiation of treatment later the same day,
and at endpoint the day after the last treatment session. PDPs followed their usual medication
schedule throughout the study and all assessments were performed in self-reported ON-state
at baseline and at endpoint.
Sit-to-stand (STS). While seated in a custom-built chair allowing only the bare feet to
exert force on a force plate (AMTI, USA, 1 kHz sampling), the participant performed trials of
six STS cycles as fast as possible [3, 27] (Fig 2A). The seat height was 120% tibia length [28].
The inter-feet distance was the width of the shoulders, the knee angle was 90˚-100˚, and the
arms were placed across the chest. At least three approved trials were performed after task
familiarization. A trial was approved if the knees were fully extended while standing, the back
touched the backrest while seated, and the feet and hands retained their positions throughout
the trial. To ensure maximal performance, an additional trial was performed if the last
approved trial was the fastest. The test-retest reliability of the completion time conducted by
the described protocol has previously been shown to be high among persons with PD (intra-
class correlation coefficient of 0.97 [27]).
Dynamic postural balance (DPB). While standing barefooted on a force plate, 46 side-
to-side movements were performed as fast as possible producing sufficient alternating ground
reaction torque around the anterior-posterior axis to exceed predetermined target torques
without lifting the feet [3, 29] (Fig 2A). Standardized feet positions with 50% leg length (tro-
chanter major to ground, barefooted) between the posterior midpoints of the calcanei and a
10˚ outward rotation of the feet were used. The target torque was 90% of the torque produced
by one-legged still stance in the standardized foot-positions. Visual on-line feedback on pro-
duced torque and target torques were provided. Standardized verbal pacing was given. The
arms were used as desired by the participant. At least three approved trials were performed
after task familiarization. A trial was approved for analysis if at least 35 of the sixth to the 46th
torque peaks exceeded 95% of the target torque. To ensure maximal performance, an addi-
tional trial was performed if the last approved trial was the fastest. The test-retest reliability of
the completion time conducted by the described protocol has previously been found to be
high among persons with PD (intraclass correlation coefficient of 0.92 [27]).
Data analysis
The analyses below were performed for the whole active and placebo groups as well as for the
PDPLow and PDPHigh subgroups of the active and placebo groups.
Raw data from the force plate of the STS test were A/D converted (16-bit, Data Translation
Inc., USA) and filtered with a zero phase second order 25 Hz low pass Butterworth filter. The
vertical ground reaction force was analyzed according to a previous study [3]. In short, the
completion time (CTSTS) was calculated as the time-period from the 1
st vertical ground reac-
tion force peak of the first repetition to the first peak of the 6th repetition (Fig 2B and 2C).
Thus, CTSTS reflected the time period of five repetitions. The rate of force development
(RFDSTS) was determined as the mean slope of the rising force of the first force peak of each of
the 2nd to the 6th repetition in the interval of 30–70% exerted peak force. Results are reported
as the mean of the two fastest approved trials in body weight per second (BW/s).
The analyses of the DPB test were performed in line with previously described principles
[3]. In short, the completion time (CTDPB) was calculated as the time from the 6
th to the 46th
torque peak (Fig 2B and 2C). The reported CTDPB was calculated as the average of the two
Effect of T-PEMF on rate of force development and movement speed in Parkinson’s disease
PLOS ONE | https://doi.org/10.1371/journal.pone.0204478 September 25, 2018 6 / 16
fastest approved trials. The rate of force development (RFDDPB) was determined as the mean
slope of the rising resultant force in the coronal plane in the interval of 30–70% of maximal
exerted force for each side-to-side movement. Results are reported as the means of the two
fastest approved trials averaged between left and right leg in BW/s.
Statistics
Group differences between active, placebo and REF at baseline were assessed by a one-way
ANOVA for age, height and weight, and by χ2 test for sex distribution. Group differences
between active and placebo at baseline were assessed by a t-test for UPDRS Total, UPDRS
Motor, disease duration and LED.
Fig 2. Illustration of the sit-to-stand (left) and dynamic postural balance task (right). A Schematic illustration of the tasks. B
Example of raw data from a representative healthy reference participant. C Example of raw data from a representative person with
Parkinson’s Disease. Completion time for dynamic postural balance (CTDPB). Completion time for sit-to-stand (CTSTS).
https://doi.org/10.1371/journal.pone.0204478.g002
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The four parameters CTSTS, RFDSTS, CTDPB and RFDDPB were tested for normal distribu-
tion (Anderson-Darling). Since CTDPB did not show a normal distribution, the log10 transfor-
mation of these data were used for further analysis. All four parameters had equal variances
across group (active and placebo) and time levels (baseline and endpoint) as assessed by the
Levene’s test. The interventional effects on CTSTS, RFDSTS, CTDPB and RFDDPB were analyzed
by repeated measure two-way ANOVAs (2 groups × 2 time points) performed as general linear
models to identify the differences between groups (active and placebo) and between time
points of testing (baseline and endpoint). The model was: Response parameter = group + sub-
ject(group) + time + group×time. Post hoc analysis of significant or a tendency of significant
interaction term (group×time) was performed by paired t-test within each group across time.
Statistics were performed in Minitab (Minitab Release 13.32). The level of significance was set
at P 0.05, and 0.05<P0.10 was presented as a tendency.
Results
Participants
Of the 97 participants originally included in the clinical trial, two withdrew, one were excluded
during the intervention, and two were lost to follow up (Fig 1). In addition, two subjects were
excluded because of lag of compliance, three subjects were incapable of performing both the
STS and DPB at baseline because of PD related motor deficits, two had developed supervening
musculoskeletal problems at follow-up and could not perform STS or DPB, and one had
changed the daily levodopa intake. Thus, 84 participants (42 active, 42 placebo) completed
baseline and endpoint testing with a treatment compliance above 80%. Of these, some had
minor supervening musculoskeletal problems making them uncomfortable in performing one
of the tasks. In total, 82 subjects (41 active, 41 placebo) were included in the STS analysis and
80 subjects (39 active, 41 placebo) were included in the DPB analysis. In addition, three sub-
jects (1 active, 2 placebo) were excluded from the analysis of RFDDPB since the data analysis
could not be conducted due to irregularity of the resultant force (Fig 1). Group descriptive var-
iables are presented in Table 1. No differences regarding age, height, body weight, disease
duration, LED, UPDRS Total, or UPDRS Motor were found between groups at baseline
(Table 1). The baseline UPDRS Total and UPDRS Motor grand average scores for the PDPLow
subgroups were 47 and 27, respectively, and 42 and 23, respectively, for the PDPHigh sub-
groups. The treatment compliance for all 84 participants included in the analyses of at least
one of the motor assessments was 98.2%.
The adverse events were benign, mild and transient and the frequency did not differ
between treatment groups [21].
Effect of treatment on motor performance
Results from the STS showed a tendency of group×time interaction effect on RFDSTS (F1,80 =
3.53, P = 0.064) and a significant main effect of time (F1,80 = 8.32, P = 0.005). Post hoc analysis
showed that the active group improved their RFDSTS by 5% from 10.1±2.3 BW/s at baseline to
10.6±2.6 BW/s at endpoint (T = -3.17, P = 0.003), whereas the placebo group did not change
from baseline to endpoint (baseline: 10.7±1.9 BW/s, endpoint: 10.8±1.8 BW/s, T = -0.76,
P = 0.450) (Fig 3B). Further, we found a significant effect of time on CTSTS as the two groups
combined improved 4.8% from 10.3±2.1 s at baseline to 9.8±1.9 s at endpoint. (F1,80 = 17.08,
P<0.001). No difference between groups (F1,80 = 0.09, P<0.760) or group×time interaction
effect (F1,80 = 0.08, P<0.773) was found (Fig 3A).
Concerning the DPB, no significant interaction or main effects were found for RFDDPB
(Fig 3D). However, the ANOVA showed a significant effect of time in CTDPB (F1,78 = 19.09,
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P<0.001) across groups but no significant main effects of group (F1,78 = 1.57, P = 0.214) or
group×time interaction effects (F1,78 = 0.12, P = 0.734). The mean CTDPB for both groups com-
bined improved 9.4% (baseline: 21.9±11.6 s, endpoint: 19.8±9.8 s) (Fig 3C).
Effect of T-PEMF on low- and high-performers
For the RFDSTS we found a significant group×time interaction (F1,36 = 4.16, P = 0.049) among
PDPHigh. Thus, the active PDPHigh group increased functional RFD during chair rise superi-
orly to the placebo group. The active PDPHigh group had a tendency towards improvement of
5% from 11.9±1.1 BW/s at baseline to 12.5±1.9 BW/s at endpoint (T = -1.95, P = 0.066),
whereas the placebo PDPHigh group did not change (baseline 12.4±1.30.30 BW/s, endpoint
12.2±1.30.31 BW/s, T = 0.86, P = 0.404) (Fig 4B). In contrast, in the PDPLow group we found
significant improvement with treatment across the active and placebo groups (F1,42 = 10.02,
P = 0.003) along with a difference between groups across time (F1,42 = 4.45, P = 0.041), but no
difference in improvement between groups (Fig 4B).
For the CTSTS and CTDPB we found improvements with treatment across groups in both
PDPLow (CTSTS: F1,30 = 10.75, P = 0.003; CTDPB: F1,16 = 10.05, P = 0.006;) and PDPHigh (CTSTS:
F1,48 = 7.07, P = 0.011; CTDPB: F1,60 = 10.15, P = 0.002) (Fig 4A & 4C). For RFDDPB the
improvement with treatment across groups was only found in the PDPLow (F1,18 = 9.88,
P = 0.006). In addition, we found a tendency of difference between groups across time in the
PDPLow (F1,18 = 3.09, P = 0.096) (Fig 4D). For PDPHigh no differences across time or groups
were found (Fig 4D).
Discussion
The main finding of this study indicates a probable positive effect of treatment with T-PEMF
on RFD during chair rise, and that this positive effect was present among the participants with
high performance levels at baseline. In addition, we found improved motor performance in
PDP from baseline to endpoint independently of the treatment received.
Our data showed that the T-PEMF treatment was superior to placebo in the PDPHigh group
for RFDSTS, whereas this was not the case among the PDPLow group indicating a group specific
effect. Muscle activation deficit is common in PD and maximal voluntary activation of the
quadriceps muscle during isometric knee extension has been shown to be negatively associated
with disease severity in terms of UPDRS Motor score [1]. Furthermore, the UPDRS Motor
Table 1. Group descriptive variables.
All PDP Active PDP Placebo PDP REF P
N 84 42 42 43 -
Females/males 37/47 18/24 19/23 20/23 0.943
Age (years) 66±8.3 67±6.5 65±9.6 66±8.1 0.775
Height (cm) 173±8.4 173±9.2 174±7.7 174±9.2 0.861
Weight (kg) 77±15.4 77±15.2 76±15.8 75±11.4 0.792
Disease duration (years) 4.9±4.0 5.4±4.6 4.3±3.6 - 0.242
LED (mg/day) 509±335 533±376 485±292 - 0.512
UPDRS Total 44±12.8 45±13.4 43±12.1 - 0.441
UPDRS Motor 25±8.1 26±8.7 24±7.4 - 0.321
Group descriptive variables at baseline for all persons with Parkinson’s disease (PDP), the active group (Active PDP), the placebo group (Placebo PDP), and the healthy
reference group (REF). Disease duration is expressed in whole years from diagnose to inclusion. Daily levodopa equivalent dose (LED). Unified Parkinson’s Disease
Rating Scale total score (UPDRS Total) and motor score (UPDRS Motor). Data are presented as the mean ± SD.
https://doi.org/10.1371/journal.pone.0204478.t001
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score has been shown to correlate with the degree of dopaminergic degeneration in PD [30].
Thus, it seems plausible that the PDPHigh group is less affected by dopaminergic degeneration
than the PDPLow group. It is therefore likely that the PDPHigh group has a higher capacity for
neuro repair than the PDPLow group. This emphasizes that early initiation of T-PEMF treat-
ment in PDP is important. However, the present results do not exclude the possibility of a pos-
itive effect of T-PEMF in the PDPLow group if the treatment period is longer than 8 weeks.
Therefore, a study on the effect of long-term treatment with T-PEMF is warranted.
The rate of force development depends on the corticospinal drive to the muscles along with
the muscle morphology. In healthy subjects, studies have shown that early explosive force
Fig 3. Results for all persons with Parkinson’s disease. A Completion time of the sit-to-stand task (CTSTS), B rate of force development
of the sit-to-stand task (RFDSTS), C completion time of the dynamic postural balance task (CTDPB), and D rate of force development of
the dynamic postural balance task (RFDDPB) for all participants with Parkinson’s disease receiving active (PDP active) or placebo (PDP
placebo) transcranial pulsed electromagnetic fields and for healthy reference participants (REF). Bodyweight (BW). Data presented as the
mean ± SD.  P0.05 for main effect of time. (#) 0.05< P< 0.1 for the group×time interaction effect.
https://doi.org/10.1371/journal.pone.0204478.g003
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generation is primarily determined by neural components in terms of agonist activation,
whereas the later phase of explosive force generation is primarily determined by muscle
mechanical components including muscle strength [31]. Both maximal voluntary contraction
force and RFD measured during electric stimulation of the quadriceps femoris muscles are
intact in persons with mild motor symptoms of PD. However, these patients have a lower vol-
untary RFD [4] indicating that mechanical muscle performance is intact, that the muscle can
be activated maximal voluntarily if the time frame is sufficient, and that what most likely con-
stitutes the problem in voluntary RFD in PD is insufficient rate of corticospinal drive to the
muscles in the early muscle contraction phase. This early phase determined by the rate of
Fig 4. Results for subgroups. A Completion time of the sit-to-stand task (CTSTS), B rate of force development of the sit-to-stand
task (RFDSTS), C completion time of the dynamic postural balance task (CTDPB), and D rate of force development of the dynamic
postural balance task (RFDDPB) for low-performers (PDPLow) and high-performers (PDPHigh) of the persons with Parkinson’s
disease receiving active or placebo transcranial pulsed electromagnetic fields. Bodyweight (BW). Data presented as the mean ± SD. 
P0.05 for main effect of time. () 0.05< P< 0.1 for the main effect of time. # P0.05 for the group×time interaction effect.
https://doi.org/10.1371/journal.pone.0204478.g004
Effect of T-PEMF on rate of force development and movement speed in Parkinson’s disease
PLOS ONE | https://doi.org/10.1371/journal.pone.0204478 September 25, 2018 11 / 16
corticospinal drive may be of utter importance, since the maximal voluntary contraction level
is usually not reached during activities of daily living. For example, around 70% of maximal
knee extensor strength is produced during self-paced rising from a chair in healthy older
adults [32].
Indeed, the agonist drive was shown to be decreased in PD and to be related to the RFD
during explosive isometric knee extension [2]. In addition, functional RFD can be improved in
PD, for example, by physical training [3]. Thus, the observed increased functional RFD in the
present study may be explained by increased rate of agonist drive to the muscles, driven by
increased corticospinal output.
Based on the literature, an increased rate of corticospinal drive could be explained by an
increased thalamocortical input to the motor cortex regulated by the basal ganglia or an
increased excitability of motor cortex. Increased intercortical facilitation, suggested to reflect
enhanced excitatory neurotransmission, has been shown as an acute effect of T-PEMF with an
intensity of 1.8 mT (75 Hz, mono pulses of 1.3 ms) in healthy subjects [17] indicating a poten-
tial of electromagnetic fields of very low intensity to induce cortical changes. To our knowl-
edge, the present clinical trial has applied daily T-PEMF stimulation for the longest period to
date, and the influence of repeated stimulation on cortical excitability in this context has not
been previously investigated. High frequent rTMS (> 1 Hz) of motor cortex in healthy partici-
pants was shown to increase the cortical excitability [33]. Whether this was also the case for
the T-PEMF regime used in the present study is uncertain since it implied electromagnetic
fields of very low intensity and did not particularly target the motor cortex. Thus, we hypothe-
size that the observed increased RFDSTS can be explained by an increased thalamocortical
input.
Furthermore, increased co-contraction has been reported among persons with PD during
both isometric [2] and dynamic assessments [34, 35]. Although an increased rate of corticosp-
inal drive seems to be a likely explanation for the increased functional RFD we cannot exclude
that reduced co-contraction of the thigh muscles play a role as well, since we did not perform
an electromyography assessment in the present study.
If the corticospinal drive has been increased by T-PEMF, it is peculiar that no significant
between-group difference in the RFDDPB was observed. This may, however, reflect the consid-
erable higher complexity of the DPB in terms of the demand for rapid integration and imple-
mentation of online visual feedback on timing and coordination of a novel, non-routine task
[36]. When evaluating the rate of resulting ground reaction force development, we measure
how fast the whole body exerts force to the ground. The more complex a task the more compo-
nents are influencing the rate of force development besides the force development of the mus-
cles. Further, the more components affecting performance the more within subject variability
is expected. Thus, the fact that no change in RFDDPB was found is not necessarily in conflict
with the finding of increased RFDSTS in PDPHigh.
The 5% increase in RFDSTS in PDPHigh is considered to be clinically relevant as any system-
atic improvement in functional rate of force development reflect improved motor control and
motor ability during daily living, although the improvement may not be perceived by all the
participants. The 5% increase may not represent the maximal obtainable effect of T-PEMF as 8
weeks of treatment is a relatively short period available to initiate structural changes in the
brain. The Danish Health Authority did not permit a longer treatment period in this first
study of homebased T-PEMF treatment in PD. We suggest the use of even longer treatment
periods in future studies to determine if the improvement can be further amplified.
For RFDSTS, CTSTS, and CTDPB, we found a significant improvement from baseline to end-
point when disregarding the treatment groups. These improvements could reflect placebo
effects, learning effects, or a mix of both. We aimed at reducing the potential effect of learning
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by familiarizing the participants to the tests before measuring and by continuing measure-
ments until reaching a plateau of performance. Test-retest reliability of the tests in PDPs are
substantial [27]. Considerable placebo effects were also reported in clinical trials of PD when
investigating invasive and non-invasive neuromodulation techniques (e.g. see [37] for review).
For example, sham rTMS was shown to reduce [11C] raclopride binding potentials in the stria-
tum of patients with PD, which indicated a placebo induced increase in dopaminergic neuro-
transmission [38]. Non-motor placebo effects of T-PEMF performed in other patient
populations have also been reported [26, 39]. Therefore, although we cannot determine the
cause of improvement across groups, we expect the learning effect to be negligible and con-
sider the improvements on CTSTS and CTDBP to be a result of the placebo effect.
Strengths and limitations
A strength of this clinical trial was the high treatment compliance and the large amount of par-
ticipants relative to previous studies of brain stimulation. To our knowledge, the present clini-
cal trial applied daily T-PEMF stimulation for the longest time period to date, which is a
strength. However, further studies on even longer treatment periods are warranted to enable
structural neural changes and thereby to get further insight concerning the neuro-mechanical
mechanisms associated with T-PEMF in PD.
Placebo effect among PDPs participating in clinical trials is a well-known phenomenon due
to the pathophysiology of the disease. In the present study, we have accounted for this by
including a placebo group receiving sham stimulation.
Three participants were not able to conduct the motor tasks because of PD-related motor
deficits. These participants were among the most severely affected PDPs.
We did not perform adjustment of the P-value in the sub group analysis as we aimed at
reducing the risk of confirming a false null-hypothesis. Thus, the reported effects of T-PEMF
on subgroup level should be interpreted as probable effects.
All assessments were performed in ON-state. Thus, we did not determine an eventual effect
of T-PEMF treatment on motor function in OFF-state. This should be considered in future
studies.
Conclusion
In this study, which is the first on the effect of long-term T-PEMF treatment on functional rate
of force development and movement speed in PD, we found that T-PEMF treatment was supe-
rior to placebo treatment to increase functional RFD during chair rise in the PDPHigh group.
Specifically, the functional RFD tended to increase in the PDPHigh group receiving T-PEMF
treatment, whereas no effect was found in the PDPHigh group receiving placebo treatment. Thus,
our results support the idea that mildly affected persons with PD have a larger potential for neu-
ral rehabilitation than more severely affected PDP. Our data on functional RFD during the more
complex DPB task and completion times of both the STS and DPB task improved but did not
allow for differentiation between T-PEMF and placebo treatments. In perspective, long-term
treatment with T-PEMF could have a potential as an add-on treatment for PD, and the results of
the present study suggest that an early treatment initiation may be beneficial. However, studies
with even longer treatment periods and in vivo mechanisms of action are recommended.
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